相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。UGT genomic diversity: beyond gene duplication
Chantal Guillemette et al.
DRUG METABOLISM REVIEWS (2010)
UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Christoph Schulz et al.
ANTI-CANCER DRUGS (2009)
Green tea (Camellia sinensis) catechins and vascular function
Rosalind J. Moore et al.
BRITISH JOURNAL OF NUTRITION (2009)
Interactions Between Herbal Medicines and Prescribed Drugs An Updated Systematic Review
Angelo A. Izzo et al.
DRUGS (2009)
Potential of pharmacokinetic profiling for detecting herbal interactions with drugs
Veronika Butterweck et al.
CLINICAL PHARMACOKINETICS (2008)
Pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity
Sarah J. Schrieber et al.
DRUG METABOLISM AND DISPOSITION (2008)
Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallocatechin gallate, in fasting and fed conditions
David R. Foster et al.
THERAPEUTIC DRUG MONITORING (2007)
Intestinal and hepatic glucuronidation of flavonoids
Li Zhang et al.
MOLECULAR PHARMACEUTICS (2007)
The role of the intestine in drug metabolism and pharmacokinetics: An industry perspective
Michael B. Fisher et al.
CURRENT DRUG METABOLISM (2007)
The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes
Bent H. Hellum et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2007)
Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives
Dale G. Nagle et al.
PHYTOCHEMISTRY (2006)
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan
NPH van Erp et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide
V D'Andrea et al.
LIFE SCIENCES (2005)
In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3 beta-glucuronidation in human liver microsomes
Y Mano et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2005)
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia)
A Ghosal et al.
DRUG METABOLISM AND DISPOSITION (2004)
An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies
J Strandell et al.
PHYTOMEDICINE (2004)
Drug-drug interactions for UDP-glucuronosyltransferase substrates:: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2004)
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium
J Lépine et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Glucuronides of tea catechins: Enzymology of biosynthesis and biological activities
H Lu et al.
DRUG METABOLISM AND DISPOSITION (2003)
The human UDP-glucuronosyltransferases: Structural aspects and drug glucuronidation
M Ouzzine et al.
DRUG METABOLISM REVIEWS (2003)
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2002)
Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3-and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics
KM Alkharfy et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2002)
Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance
DC Kemp et al.
DRUG METABOLISM AND DISPOSITION (2002)
分享论文
